Want to see FULC full AI Analyst Report?
FULC Stock Chart & Stats
$3.86
-$0.04(-1.06%)
At close: 4:00 PM EDT
$3.86
-$0.04(-1.06%)
Day’s Range― - ―
52-Week Range$2.83 - $15.74
Previous CloseN/A
Volume572.86K
Average Volume (3M)1.39M
Market Cap
$278.48M
Enterprise Value-$34.44M
Total Cash (Recent Filing)$318.84M
Total Debt (Recent Filing)$5.28M
Price to Earnings (P/E)―
Beta1.93
Next Earnings
Oct 29, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.21
Shares Outstanding76,297,260
10 Day Avg. Volume1,463,522
30 Day Avg. Volume1,391,745
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)2.05
Price to Sales (P/S)0.00
P/FCF Ratio-11.87
Enterprise Value/Market Cap-0.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.37
Enterprise Value/Ebitda0.44
Forecast
1Y Price Target
$3.00Price Target Upside-22.28% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)-0.6
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Substantial EquityVery low leverage and a large equity base provide financial flexibility during clinical development and reduce near-term solvency pressure. This balance-sheet support can help the company fund strategic actions and absorb operating volatility, although it does not eliminate cash-burn risk.
Merger Financing Extends Development RunwayThe committed financing gives the post-merger company a multi-year funding runway, reducing immediate reliance on additional capital raises. It is intended to support SLTE-1009 through Phase 1 and Phase 2 studies and advance the broader pipeline, strengthening development continuity.
Governance And Audit ContinuityMulti-year director terms and continued independent audit oversight support organizational continuity while Fulcrum undergoes a major strategic transition. Stable governance can improve accountability, preserve institutional knowledge, and help maintain financial stewardship through the merger process.
Bears Say
No Current Commercial RevenueThe shift to zero revenue leaves Fulcrum without a stable commercial base to offset research and development costs. Large continuing losses make future earnings dependent on clinical progress, partnerships, financing, or the merger rather than recurring product sales.
Persistent And Worsening Cash BurnSustained negative operating and free cash flow consumes the capital base needed for clinical development and corporate operations. The sharp deterioration in 2025 increases dependence on external funding or strategic transactions, limiting flexibility if development plans or financing assumptions change.
Pipeline Setback And Reduced Fulcrum OwnershipDiscontinuing pociredir removes a clinical program and the associated restructuring signals a materially narrowed standalone platform. The merger shifts strategic control and most ownership to Slate, leaving Fulcrum holders primarily exposed to Slate’s pipeline and its execution.
Fulcrum Therapeutics News
FULC FAQ
What was Fulcrum Therapeutics’s price range in the past 12 months?
Fulcrum Therapeutics lowest stock price was $2.83 and its highest was $15.74 in the past 12 months.
What is Fulcrum Therapeutics’s market cap?
Fulcrum Therapeutics’s market cap is $278.48M.
When is Fulcrum Therapeutics’s upcoming earnings report date?
Fulcrum Therapeutics’s upcoming earnings report date is Oct 29, 2026 which is in 9 days.
How were Fulcrum Therapeutics’s earnings last quarter?
Fulcrum Therapeutics released its earnings results on Aug 05, 2026. The company reported -$0.342 earnings per share for the quarter, missing the consensus estimate of -$0.257 by -$0.085.
Is Fulcrum Therapeutics overvalued?
According to Wall Street analysts Fulcrum Therapeutics’s price is currently Overvalued.
Does Fulcrum Therapeutics pay dividends?
Fulcrum Therapeutics does not currently pay dividends.
What is Fulcrum Therapeutics’s EPS estimate?
Fulcrum Therapeutics’s EPS estimate is -0.07.
How many shares outstanding does Fulcrum Therapeutics have?
Fulcrum Therapeutics has 76,297,260 shares outstanding.
What happened to Fulcrum Therapeutics’s price movement after its last earnings report?
Fulcrum Therapeutics reported an EPS of -$0.342 in its last earnings report, missing expectations of -$0.257. Following the earnings report the stock price went down -0.789%.
Which hedge fund is a major shareholder of Fulcrum Therapeutics?
Currently, no hedge funds are holding shares in FULC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fulcrum Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$3.00 (-22.28% Downside)
$3.00 (-22.28% Downside)
Blogger Sentiment
Bullish
FULC Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 5.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $594.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 5.1%
Last 30 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.71%
12-Months-Change
Fundamentals
Return on Equity
-28.54%
Trailing 12-Months
Asset Growth
41.56%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Fulcrum Therapeutics
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
FULC Stock 12 Month Forecast
Average Price Target
$3.00
▼(-22.28% Downside)
Technical Analysis
Monopar Therapeutics Inc
―
ADC Therapeutics
―
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
18.23% Insiders
7.44% Mutual Funds
1.59% Other Institutional Investors
60.86% Public Companies and
Individual Investors